Cytek Biosciences Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)The following documents are filed as part of this Annual Report on Form 10-K:
(1)Consolidated Financial Statements
The consolidated financial statements filed as part of this Annual Report on Form 10-K are included in Part II, Item 8 of this Annual Report on Form 10-K.
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)
Consolidated Balance Sheet
Consolidated Statements of Operations and Comprehensive (Loss) Income
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity
Consolidated Statements of Cash Flows
Notes to consolidated financial statements
(2)Financial Statement Schedules
Financial statement schedules have been omitted in this Annual Report on Form 10-K because they are not applicable, not required under the instructions or the information requested is set forth in the financial statements or related notes thereto in Part II, Item 8 of this Annual Report on Form 10-K.
(3)List of Exhibits required by Item 601 of Regulation S-K
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Number · Exhibit Title · Form · File No. · Exhibit · FilingDate · FiledHerewith | |||||
| 2.1+ | Asset Purchase Agreement, dated February 13, 2023, by and between Cytek, Inc. and Luminex Corporation | 10-K | 001-40632 | 10.16 | 03/01/2023 |
| 3.1 | Amended and Restated Certificate of Incorporation | 8-K | 001-40632 | 3.1 | 07/27/2021 |
| 3.2 | Amended and Restated Bylaws | 8-K | 001-40632 | 3.2 | 07/27/2021 |
| 4.1 | Reference is made to Exhibits 3.1 and 3.2. | ||||
| 4.2 | Form of common stock certificate of Cytek Biosciences, Inc. | S-1/A | 333-257663 | 4.1 | 07/19/2021 |
| 4.3 | Description of Securities. | 10-K | 001-40632 | 4.3 | 03/01/2023 |
| 10.1 | Cytek Biosciences, Inc. 2015 Equity Incentive Plan, as amended. | S-1 | 333-257663 | 10.2 | 07/02/2021 |
| 10.2 | Forms of Option Agreement, Notice of Stock Option Grant and Exercise Notice under Cytek Biosciences, Inc. 2015 Equity Incentive Plan. | S-1 | 333-257663 | 10.3 | 07/02/2021 |
| 10.3 | Cytek Biosciences, Inc. 2021 Equity Incentive Plan. | S-1/A | 333-257663 | 10.4 | 07/19/2021 |
| 10.4 | Forms of Option Agreement and Notice of Stock Option Grant under 2021 Equity Incentive Plan. | S-1/A | 333-257663 | 10.5 | 07/19/2021 |
| 10.5 | Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan | 10-Q | 001-40632 | 10.2 | 11/12/2021 |
| 10.6 | Forms of Option Agreement and Notice of Stock Option Grant under 2021 Equity Incentive Plan, effective August 23, 2022. | 10-Q | 001-40632 | 10.1 | 11/09/2022 |
| 10.7 | Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan, effective August 23, 2022. | 10-Q | 001-40632 | 10.2 | 11/09/2022 | |
| 10.8 | Cytek Biosciences, Inc. 2021 Employee Stock Purchase Plan. | S-1/A | 333-257663 | 10.6 | 07/19/2021 | |
| 10.9 | Form of Indemnification Agreement, by and between Cytek Biosciences, Inc. and each of its directors and executive officers. | S-1/A | 333-257663 | 10.7 | 07/19/2021 | |
| 10.10 | Offer letter, by and between Cytek Biosciences, Inc. and Valerie Barnett, dated January 12, 2021. | 10-Q | 001-40632 | 10.1 | 05/09/2023 | |
| 10.11 | Offer letter, by and between Cytek Biosciences, Inc. and Allen Poirson, Ph.D., dated March 23, 2021. | 10-Q | 001-40632 | 10.2 | 05/08/2024 | |
| 10.12 | Offer letter, by and between Cytek Biosciences, Inc. and William McCombe, dated March 18, 2024. | 8-K | 001-40632 | 10.1 | 03/19/2024 | |
| 10.13 | Cytek Biosciences, Inc. Second Amended and Restated Severance Benefit Plan. | 10-Q | 001-40632 | 10.1 | 05/08/2024 | |
| 10.14+ | Supply Agreement between the Registrant and Cytek (Wuxi) Biosciences Co., Ltd, a China subsidiary of Cytek Biosciences, Inc., and Coherent NA, Inc. dated August 25, 2021. | 10-Q | 001-40632 | 10.1 | 11/12/2021 | |
| 10.15+ | Supply and License Agreement, by and between Biotium, Inc. and Cytek Biosciences, Inc., dated as of September 1, 2020. | S-1 | 333-257663 | 10.11 | 07/02/2021 | |
| 10.16+ | Settlement, License, and Equity Issuance Agreement, by and between Becton, Dickinson and Company and Cytek Biosciences, Inc., dated October 5, 2020. | S-1 | 333-257663 | 10.12 | 07/02/2021 | |
| 10.17 | Lease, by and between SNH Medical Office Properties Trust and Cytek Biosciences, Inc., dated November 20, 2020. | S-1 | 333-257663 | 10.14 | 07/02/2021 | |
| 10.18 | First Amendment to Lease, by and between DHC ZB Properties LLC and Cytek Biosciences, Inc., dated October 28, 2024. | X | ||||
| 10.19 | Equity Distribution Agreement, by and between the Company and Piper Sandler & Co. dated August 26, 2022. | S-3 | 333-267118 | 1.2 | 08/26/2022 | |
| 19.1 | Insider Trading Policy | X | ||||
| 21.1 | List of Subsidiaries of the Registrant | X | ||||
| 23.1 | Consent of Deloitte & Touche LLP, independent registered public accounting firm. | X | ||||
| 24.1 | Power of Attorney (incorporated by reference to the signatures page of this Annual Report on Form 10-K) | X | ||||
| 31.1 | Certification of Principal Executive Officer required by Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 · Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. · X | ||||||
|---|---|---|---|---|---|---|
| 32.1* · Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* · X | ||||||
| 32.2* · Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* · X | ||||||
| 97.0 | Cytek Biosciences, Inc. Incentive Compensation Recoupment Policy | 10-K | 001-40632 | 97 | 03/13/2024 | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X | ||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibits 101). | X | ||||
+Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the Registrant has determined that the omitted information is both not material and is the type that the Registrant treats as private and confidential.
*As contemplated by SEC Release No. 33-8212, these exhibits are furnished with this Annual Report on Form 10-K and are not deemed filed with the SEC and are not incorporated by reference in any filing of Cytek Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language contained in such filings.
The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.